Lonza Group AG (LZAGF)
USD 588.7
(0.0%)
USD 588.7
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.5 Billion CHF | -23.65% |
| 2022 | 2.1 Billion CHF | 47.71% |
| 2021 | 1.35 Billion CHF | -8.98% |
| 2020 | 1.43 Billion CHF | -4.33% |
| 2019 | 1.33 Billion CHF | 3.73% |
| 2018 | 1.43 Billion CHF | 45.53% |
| 2017 | 1.02 Billion CHF | 23.3% |
| 2016 | 807 Million CHF | 11.93% |
| 2015 | 721 Million CHF | -7.56% |
| 2014 | 780 Million CHF | 49.43% |
| 2013 | 522 Million CHF | -16.75% |
| 2012 | 632 Million CHF | 15.68% |
| 2011 | 542 Million CHF | -16.87% |
| 2010 | 652 Million CHF | 23.72% |
| 2009 | 527 Million CHF | -35.18% |
| 2008 | 813 Million CHF | 18.86% |
| 2007 | 688 Million CHF | 31.79% |
| 2006 | 519 Million CHF | 4.01% |
| 2005 | 499 Million CHF | 30.29% |
| 2004 | 383 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 412 Million CHF | 0.0% |
| 2024 Q1 | 412 Million CHF | -59.69% |
| 2023 Q2 | 912 Million CHF | 102.89% |
| 2023 Q1 | 449.5 Million CHF | -62.64% |
| 2023 Q3 | 508 Million CHF | -44.3% |
| 2023 FY | - CHF | -23.65% |
| 2023 Q4 | 1.02 Billion CHF | 101.18% |
| 2022 Q3 | 482 Million CHF | -50.05% |
| 2022 Q4 | 1.2 Billion CHF | 149.59% |
| 2022 FY | - CHF | 47.71% |
| 2022 Q1 | 467 Million CHF | -41.7% |
| 2022 Q2 | 965 Million CHF | 106.64% |
| 2021 Q4 | 801 Million CHF | 249.02% |
| 2021 Q3 | 229.5 Million CHF | -58.87% |
| 2021 Q2 | 558 Million CHF | 31.6% |
| 2021 Q1 | 424 Million CHF | -18.15% |
| 2021 FY | - CHF | -8.98% |
| 2020 Q3 | 335.5 Million CHF | -61.96% |
| 2020 FY | - CHF | -4.33% |
| 2020 Q4 | 518 Million CHF | 54.4% |
| 2020 Q1 | 374.5 Million CHF | -49.25% |
| 2020 Q2 | 882 Million CHF | 135.51% |
| 2019 Q3 | 296 Million CHF | -23.61% |
| 2019 FY | - CHF | 3.73% |
| 2019 Q4 | 738 Million CHF | 149.32% |
| 2019 Q1 | 387.5 Million CHF | -14.17% |
| 2019 Q2 | 387.5 Million CHF | 0.0% |
| 2018 FY | - CHF | 45.53% |
| 2018 Q3 | 451.5 Million CHF | 55.42% |
| 2018 Q2 | 290.5 Million CHF | 0.0% |
| 2018 Q1 | 290.5 Million CHF | -48.17% |
| 2018 Q4 | 451.5 Million CHF | 0.0% |
| 2017 FY | - CHF | 23.3% |
| 2017 Q2 | 193.5 Million CHF | 0.0% |
| 2017 Q1 | 193.5 Million CHF | -18.53% |
| 2017 Q3 | 259.5 Million CHF | 34.11% |
| 2017 Q4 | 560.5 Million CHF | 115.99% |
| 2016 FY | - CHF | 11.93% |
| 2016 Q2 | 216.75 Million CHF | 0.0% |
| 2016 Q1 | 216.75 Million CHF | -3.13% |
| 2016 Q4 | 237.5 Million CHF | 1.82% |
| 2016 Q3 | 233.25 Million CHF | 7.61% |
| 2015 Q2 | 167.5 Million CHF | 0.0% |
| 2015 FY | - CHF | -7.56% |
| 2015 Q3 | 224.5 Million CHF | 34.03% |
| 2015 Q1 | 167.5 Million CHF | -10.43% |
| 2015 Q4 | 223.75 Million CHF | -0.33% |
| 2014 Q2 | 179.25 Million CHF | 0.0% |
| 2014 Q1 | 179.25 Million CHF | -3.5% |
| 2014 FY | - CHF | 49.43% |
| 2014 Q4 | 187 Million CHF | -0.13% |
| 2014 Q3 | 187.25 Million CHF | 4.46% |
| 2013 Q3 | 183.75 Million CHF | 14.66% |
| 2013 FY | - CHF | -16.75% |
| 2013 Q1 | 160.25 Million CHF | 0.0% |
| 2013 Q4 | 185.75 Million CHF | 1.09% |
| 2013 Q2 | 160.25 Million CHF | 0.0% |
| 2012 FY | - CHF | 15.68% |
| 2011 FY | - CHF | -16.87% |
| 2010 FY | - CHF | 23.72% |
| 2009 FY | - CHF | -35.18% |
| 2008 FY | - CHF | 18.86% |
| 2007 FY | - CHF | 31.79% |
| 2006 FY | - CHF | 4.01% |
| 2005 FY | - CHF | 30.29% |
| 2004 FY | - CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 129420.722% |
| Arrayit Corporation | -3.07 Million USD | 48970.916% |
| Atlantic International Corp. | -5.38 Million USD | 28005.803% |
| Biocept, Inc. | -30.24 Million USD | 5073.381% |
| Bioqual, Inc. | 3.03 Million USD | -49500.295% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 198680.624% |
| DermTech, Inc. | -97.89 Million USD | 1636.371% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 48.389% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 7529.928% |
| iMD Companies, Inc. | -154.65 Thousand USD | 972561.997% |
| IDenta Corp. | 71.58 Thousand USD | -2100840.115% |
| Interpace Biosciences, Inc. | 3.83 Million USD | -39097.29% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -3887209.382% |
| InVitro International | 6680.00 USD | -22514870.06% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 27767.403% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | 12395023.356% |
| Medical Imaging Corp. | -896.74 Thousand USD | 167818.251% |
| NovelStem International Corp. | -3.78 Million USD | 39827.413% |
| Optigenex Inc. | -1.18 Million USD | 126835.45% |
| PharmChem, Inc. | 1.05 Million USD | -142620.225% |
| Proteome Sciences plc | -1.13 Million USD | 132377.924% |
| Response Genetics, Inc | -19.66 Million USD | 7747.717% |
| Rennova Health, Inc. | -234.81 Thousand USD | 640604.227% |
| RushNet, Inc. | -614.85 Thousand USD | 244711.711% |
| ScreenPro Security Inc. | -3.43 Million USD | 43885.986% |
| Stella Diagnostics Inc. | -5.7 Million USD | 26451.615% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 14744.396% |
| Todos Medical Ltd. | -9.39 Million USD | 16110.219% |